William E Ewing

US Patent:

6559313, May 6, 2003

Filed:

Mar 22, 2002

Appl. No.:

10/104133

Inventors:

Michael R. Myers - Fishers PA
Martin P. Maguire - Cambridge MA
Alfred P. Spada - Carlsbad CA
William R. Ewing - Downingtown PA
Henry W. Pauls - Collegeville PA
Yong Mi Choi-Sledeski - Belle Mead NJ

Assignee:

Aventis Pharma Deutschland GmbH - Frankfurt am Main

International Classification:

C07D47334

US Classification:

5462791

Abstract:

This invention is directed to intermediates of the formula wherein Z is 4-trifluoromethylpyridin-2-yl or 5-trifluoromethylpyridin-2-yl which are useful in the preparation of compounds useful as antihypertensive, anti-ischemic, cardioprotective, and antilipolytic agents.

US Patent:

20030176390, Sep 18, 2003

Filed:

May 14, 2002

Appl. No.:

10/145207

Inventors:

Andreas Herling - Bad Camberg, DE
Gerhard Jaehne - Frankfurt, DE
Martin Maguire - Cambridge MA, US
Alfred Spada - Carlsbad CA, US
Michael Myers - Fishers IN, US
Yong Choi-Sledeski - Belle Mead NJ, US
Heinz Pauls - Flemington NJ, US
William Ewing - Yardley PA, US

International Classification:

A61K031/7076
A61K031/52
A61K031/7052
A61K031/4745

US Classification:

514/046000, 514/043000, 514/263200, 514/263220, 514/303000

Abstract:

This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.

US Patent:

52492419, Sep 28, 1993

Filed:

Jul 9, 1991

Appl. No.:

7/728907

Inventors:

Jerry Silverman - Waban MA
Jonathan Mooney - Waltham MA
William Ewing - Stow MA
Darryl Sato - San Diego CA

Assignee:

The United States of America as represented by the Secretary of the Air
Force - Washington DC

International Classification:

G06K 938

US Classification:

382 51

Abstract:

A histogram projection system which automatically optimizes, tracks changes in luminance and adjusts in real time the display of wide dynamic range imagery from IR cameras. It is computationally simpler than and offers markedly superior results to the standard available technique for this purpose, histogram equalization. The new technique assigns display dynamic range equally to each occupied intensity level in the raw data in contrast to the old procedure which assigns dynamic range in proportion to the number of pixels at given levels. Less shot noise and greater resolution of image detail for smaller objects or targets are the main improvements from the new algorithm. By the expedient of undersampling the image pixels in carrying out the histogram processing, one can in effect gradually increase the degree of dynamic range assigned to majority or background pixel levels, thereby enhancing the contrast in background regions when desired.

US Patent:

20220220220, Jul 14, 2022

Filed:

Jan 7, 2022

Appl. No.:

17/570649

Inventors:

- Princeton NJ, US
- Titusville NJ, US
Ginger Chao Rakestraw - Cambridge MA, US
Christina Terragni - Cambridge MA, US
Andrew Karl Dilger - Princeton NJ, US
Jason Robert Pinckney - Cambridge MA, US
Steven Sheriff - Princeton NJ, US
Kevin Kish - Princeton NJ, US
Yongmi An - Princeton NJ, US
William R. Ewing - Princeton NJ, US
Aaron Paul Yamniuk - Vancouver, CA

International Classification:

C07K 16/36
C07K 16/44
A61P 7/04
G01N 33/86
G01N 33/94

Abstract:

The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.